Bulletin
Investor Alert

New York Markets Open in:

Moderna Inc.

NAS: MRNA

GO
/marketstate/country/us

Before the Bell

 --Real time quotes

May 13, 2021, 5:53 a.m.

/zigman2/quotes/205619834/composite

$

152.31

Change

-0.37 -0.24%

Volume

Volume 661

Real time quotes

/zigman2/quotes/205619834/composite

Previous close

$ 152.68

$ 152.68

Change

-6.31 -3.97%

Day low

Day high

$151.15

$158.91

Open

52 week low

52 week high

$46.13

$189.26

Open

Company Description

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therap...

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Valuation

P/E Ratio (with extraordinary items)

114.29

Price to Sales Ratio

49.59

Price to Book Ratio

16.27

Price to Cash Flow Ratio

19.77

Enterprise Value to Sales

44.15

Total Debt to Enterprise Value

0.01

Efficiency

Revenue/Employee

617,996.00

Income Per Employee

-574,665.00

Receivables Turnover

1.13

Total Asset Turnover

0.18

Liquidity

Current Ratio

1.43

Quick Ratio

1.42

Cash Ratio

1.05

Profitability

Gross Margin

95.12

Operating Margin

-94.99

Pretax Margin

-92.67

Net Margin

-92.99

Return on Assets

-16.74

Return on Equity

-39.99

Return on Total Capital

-37.14

Return on Invested Capital

-36.66

Capital Structure

Total Debt to Total Equity

9.28

Total Debt to Total Capital

8.49

Total Debt to Total Assets

3.24

Long-Term Debt to Equity

8.09

Long-Term Debt to Total Capital

7.41

Officers and Executives

Name Age Officer Since Title
Mr. Stéphane Bancel 47 2011 President, Founding CEO & Director
Dr. Stephen Hoge 43 2013 SVP-Corporate Development & New Drug Concepts
Mr. David W. Meline 62 2020 Chief Financial Officer
Mr. Juan Andres 54 2017 Chief Technical Operations & Quality Officer
Dr. Tal Zaks 54 2015 Chief Medical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/10/2021 Juan Andres
See remarks
5,000   Disposition at $164.38 per share. 821,900
05/10/2021 Tal Zaks
Chief Medical Officer
200   Disposition at $163.12 per share. 32,624
05/10/2021 Tal Zaks
Chief Medical Officer
100   Disposition at $161.64 per share. 16,164
05/10/2021 Tal Zaks
Chief Medical Officer
200   Disposition at $159.63 per share. 31,926
05/10/2021 Tal Zaks
Chief Medical Officer
1,585   Disposition at $158.88 per share. 251,824
05/10/2021 Tal Zaks
Chief Medical Officer
985   Disposition at $157.48 per share. 155,117
05/10/2021 Tal Zaks
Chief Medical Officer
600   Disposition at $156.6 per share. 93,960
05/10/2021 Juan Andres
See remarks
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
05/10/2021 Tal Zaks
Chief Medical Officer
3,670   Derivative/Non-derivative trans. at $12.21 per share. 44,810
05/07/2021 Stéphane Bancel
Chief Executive Officer; Director
533   Disposition at $168.48 per share. 89,799
05/07/2021 Stéphane Bancel
Chief Executive Officer; Director
600   Disposition at $166.83 per share. 100,098
05/07/2021 Stéphane Bancel
Chief Executive Officer; Director
781   Disposition at $165.76 per share. 129,458
05/07/2021 Stéphane Bancel
Chief Executive Officer; Director
788   Disposition at $164.64 per share. 129,736
05/07/2021 Stéphane Bancel
Chief Executive Officer; Director
4,149   Disposition at $163.54 per share. 678,527
05/07/2021 Stéphane Bancel
Chief Executive Officer; Director
3,595   Disposition at $162.81 per share. 585,301
05/07/2021 Stéphane Bancel
Chief Executive Officer; Director
600   Disposition at $161.18 per share. 96,708
05/06/2021 Stéphane Bancel
Chief Executive Officer; Director
10,000   Disposition at $147.82 per share. 1,478,200
05/06/2021 Lori M. Henderson
General Counsel and Secretary
6,600   Disposition at $147.82 per share. 975,612
05/06/2021 Lori M. Henderson
General Counsel and Secretary
6,600   Derivative/Non-derivative trans. at $20.93 per share. 138,138
05/05/2021 Stéphane Bancel
Chief Executive Officer; Director
2,000   Gift at $0 per share. 0
05/05/2021 Stéphane Bancel
Chief Executive Officer; Director
9,000   Disposition at $178.34 per share. 1,605,060
05/05/2021 Juan Andres
See remarks
5,000   Disposition at $178.34 per share. 891,700
05/05/2021 Juan Andres
See remarks
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
05/04/2021 Lori M. Henderson
General Counsel and Secretary
6,600   Disposition at $185.25 per share. 1,222,650
05/04/2021 Lori M. Henderson
General Counsel and Secretary
6,600   Derivative/Non-derivative trans. at $20.93 per share. 138,138
05/03/2021 Stephen Hoge
President
20,000   Disposition at $183.66 per share. 3,673,200
05/03/2021 Juan Andres
See remarks
5,000   Disposition at $183.66 per share. 918,300
05/03/2021 Tal Zaks
Chief Medical Officer
916   Disposition at $188 per share. 172,208
05/03/2021 Tal Zaks
Chief Medical Officer
1,924   Disposition at $187.1 per share. 359,980
05/03/2021 Tal Zaks
Chief Medical Officer
1,089   Disposition at $186.04 per share. 202,597
05/03/2021 Tal Zaks
Chief Medical Officer
800   Disposition at $184.77 per share. 147,816
05/03/2021 Tal Zaks
Chief Medical Officer
271   Disposition at $183.42 per share. 49,706
05/03/2021 Stephen Hoge
President
10,000   Derivative/Non-derivative trans. at $0.99 per share. 9,900
05/03/2021 Stephen Hoge
President
10,000   Derivative/Non-derivative trans. at $0.99 per share. 9,900
05/03/2021 Juan Andres
See remarks
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
05/03/2021 Tal Zaks
Chief Medical Officer
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
04/30/2021 Stéphane Bancel
Chief Executive Officer; Director
100   Disposition at $183.74 per share. 18,374
04/30/2021 Stéphane Bancel
Chief Executive Officer; Director
800   Disposition at $182.84 per share. 146,272
04/30/2021 Stéphane Bancel
Chief Executive Officer; Director
4,845   Disposition at $182.05 per share. 882,032
04/30/2021 Stéphane Bancel
Chief Executive Officer; Director
1,400   Disposition at $180.41 per share. 252,574
04/30/2021 Stéphane Bancel
Chief Executive Officer; Director
1,809   Disposition at $179.45 per share. 324,625
04/30/2021 Stéphane Bancel
Chief Executive Officer; Director
1,792   Disposition at $178.35 per share. 319,603
04/30/2021 Stéphane Bancel
Chief Executive Officer; Director
300   Disposition at $175.27 per share. 52,581
04/29/2021 Stéphane Bancel
Chief Executive Officer; Director
10,000   Disposition at $182.49 per share. 1,824,900
04/29/2021 Lori M. Henderson
General Counsel and Secretary
6,600   Disposition at $182.49 per share. 1,204,434
04/29/2021 Lori M. Henderson
General Counsel and Secretary
6,600   Derivative/Non-derivative trans. at $20.93 per share. 138,138
04/28/2021 Stéphane Bancel
Chief Executive Officer; Director
2,000   Gift at $0 per share. 0
04/28/2021 Stéphane Bancel
Chief Executive Officer; Director
9,000   Disposition at $182.32 per share. 1,640,880
04/28/2021 Juan Andres
See remarks
5,000   Disposition at $182.32 per share. 911,600
04/28/2021 Juan Andres
See remarks
5,000   Derivative/Non-derivative trans. at $12.21 per share. 61,050
04/27/2021 Lori M. Henderson
General Counsel and Secretary
6,600   Disposition at $178.29 per share. 1,176,714
04/27/2021 Lori M. Henderson
General Counsel and Secretary
6,600   Derivative/Non-derivative trans. at $20.93 per share. 138,138
/news/latest/company/us/mrna

MarketWatch News on MRNA

  1. Moderna Inc. stock underperforms Wednesday when compared to competitors

    4:31 p.m. May 12, 2021

    - MarketWatch Automation

  2. Moderna has new 25 mln dose COVID-19 vaccine supply agreement with Australia

    7:06 a.m. May 12, 2021

    - Tomi Kilgore

  3. Moderna Inc. stock rises Tuesday, outperforms market

    4:31 p.m. May 11, 2021

    - MarketWatch Automation

  4. The Logic Behind the Tech Rout

    4:24 p.m. May 11, 2021

  5. Wall Street Now Expects Big Sales of Covid Vaccines Next Year

    11:30 a.m. May 11, 2021

    - Josh Nathan-Kazis

  6. Moderna Inc. stock underperforms Monday when compared to competitors

    4:31 p.m. May 10, 2021

    - MarketWatch Automation

  7. EU Ditches AstraZeneca Vaccine. It's Pivoting to Pfizer.

    8:21 a.m. May 10, 2021

    - Josh Nathan-Kazis

  8. COVID-19 was never going to have a tidy Hollywood ending

    6:04 p.m. May 8, 2021

    - Quentin Fottrell

  9. Loading more headlines...
/news/nonmarketwatch/company/us/mrna

Other News on MRNA

  1. Moderna: A Suspension Of Intellectual Property Is A Real Threat

    48 min ago

    - Seeking Alpha

  2. CDC Recommends Covid-19 Vaccine for 12- to 15-Year-Olds

    6:52 p.m. May 12, 2021

    - Jared S. Hopkins

  3. Moderna Delivers More Bad News

    8:07 a.m. May 12, 2021

    - Seeking Alpha

  4. 2 Best Biotech Stocks to Buy Now

    6:16 a.m. May 12, 2021

    - Motley Fool

  5. Why Novavax Stock Sank Again on Tuesday

    5:51 p.m. May 11, 2021

    - Motley Fool

  6. Why Moderna Shareholders Should Savor First Quarterly Profit Results

    11:19 a.m. May 11, 2021

    - InvestorPlace.com

  7. 7 Stocks to Start your Robinhood Portfolio With Just $2,000

    10:51 a.m. May 11, 2021

    - InvestorPlace.com

  8. Takeda may double imports of Moderna COVID-19 vaccine: CEO

    9:15 a.m. May 11, 2021

    - Seeking Alpha

  9. Wall Street Breakfast: Look Out Below

    7:06 a.m. May 11, 2021

    - Seeking Alpha

  10. The Moderna CEO Makes a Surprising Prediction About 2022

    6:15 a.m. May 11, 2021

    - Motley Fool

  11. Loading more headlines...

At a Glance

Moderna, Inc.

200 Technology Square

Cambridge, Massachusetts 02139

Phone

1 6177146500

Industry

-

Sector

-

Fiscal Year-end

12/2021

Revenue

$803.40M

Net Income

$-747.06M

2020 Sales Growth

1234.3%

Employees

1,300

/news/pressrelease/company/us/mrna

Press Releases on MRNA

  1. Nasdaq 100 Movers: CTSH, FOXA

    10:47 a.m. May 6, 2021

    - MarketNewsVideo.com

  2. Nasdaq 100 Movers: CTSH, FOXA

    10:44 a.m. May 6, 2021

    - MarketNewsVideo.com

  3. Moderna Plunges on Numbers, Vaccine Effectiveness

    10:13 a.m. May 6, 2021

    - Baystreet.ca

  4. Moderna, Inc. to Host Earnings Call

    6:15 a.m. May 6, 2021

    - ACCESSWIRE

  5. Vaxart Up on New Test Data

    10:12 a.m. May 4, 2021

    - Baystreet.ca

  6. 4 Top Biotech Stocks To Watch In May 2021

    9:50 p.m. May 3, 2021

    - StockMarket.com

  7. Nasdaq 100 Movers: SWKS, MRNA

    11:56 a.m. May 3, 2021

    - MarketNewsVideo.com

  8. Loading more headlines...
Link to MarketWatch's Slice.